Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

Executive Summary

As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.

You may also be interested in...



Alzheimer's Early Approval? Skepticism Over Biogen/Eisai's BAN2401 Data Clouds Chances

18-month Phase II data on amyloid-targeting antibody BAN2401, presented at AAIC, raised more questions than they answered – and seemed to take the wind out of the sails for an early regulatory filing.

Eisai Refocuses AiM As It Builds US Immuno-Dementia Research

Amid multiple industry drug failures in the sector, Eisai is opening a new US research facility to discover innovative therapies for dementia based on a long-standing immunology hypothesis.

Shionogi's Oral COVID Drug Set For Global Access Through MPP

Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel